SOURCE: VIVUS, Inc.

December 15, 2014 07:00 ET

VIVUS Announces Favorable Formulary Positioning for Qsymia

MOUNTAIN VIEW, CA--(Marketwired - December 15, 2014) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today announced that Qsymia is the sole anti-obesity agent listed on the CVS/Caremark Performance Drug List, or PDL. Preferred brand-name medicines are listed on the PDL to help identify products that are clinically appropriate and cost-effective as defined by CVS/Caremark.

"We are pleased that Qsymia is recognized as the preferred anti-obesity therapy on the CVS/Caremark PDL," said Seth H. Z. Fischer, CEO. "We believe Qsymia is an outstanding option for patients with obesity and complications associated with this disease."

About Qsymia
Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. Additional information is available at www.qsymia.com.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information
Qsymia® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS
VIVUS is a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including risks and uncertainties related to Qsymia as the preferred anti-obesity therapy on the CVS/Caremark PDL and Qsymia as an outstanding option for patients with obesity and complications associated with this disease. These risks and uncertainties could cause actual results to differ materially from those referred to in these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2013 as filed on February 28, 2014 and as amended by the Form 10-K/A filed on April 30, 2014, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.

Contact Information

  • VIVUS, Inc.
    Dana B. Shinbaum
    Corporate Development & Investor Relations
    shinbaum@vivus.com

    Investor Relations: The Trout Group
    Brian Korb
    Senior Vice President
    bkorb@troutgroup.com
    646-378-2923